News for Healthier Living

ASCO: New Antibody-Drug Conjugate Shows Promising Safety and Response Rates for Patients with Rare Blood Cancer

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

June 2, 2025


July 19 2025

July 18 2025

July 17 2025

July 16 2025

July 15 2025

July 14 2025

July 13 2025

July 12 2025

July 11 2025

July 10 2025

July 9 2025

July 8 2025

July 7 2025

July 6 2025